FDA Poised to Ease Restrictions on Injectable Peptides Af Pharmacy Purchasing & Products Magazine The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Compounded Peptides Explained: APIs, COAs, 503A vs 503B & How Pharmacies Should Source Safely Why 503B SKNV Industry Update: Interim 503A and 503B Bulks Lists New Revisions